We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Stocks to Buy Following Robust Quarterly Results
Read MoreHide Full Article
The 2024 Q3 earnings season continues to chug along, with a decent chunk of S&P 500 companies already delivering their results.
And throughout the period, several companies, including Pfizer (PFE - Free Report) , Philip Morris (PM - Free Report) , and Tenet Healthcare (THC - Free Report) , have stolen the spotlight, with each raising guidance.
Let’s take a closer look at the reports.
Pfizer Sees Bullish Outlook
Pfizer shares have largely been disappointing in 2024, up 3% and widely underperforming relative to the S&P 500. Still, the recent set of favorable results could perk shares up in the near term, with the company raising its current-year sales guidance by a solid $1.5 billion while also raising its adjusted EPS outlook.
Image Source: Zacks Investment Research
Strong demand for Paxlovid following a recent wave of COVID-19 helped drive the better-than-expected results, with successful cost-cutting measures also providing tailwinds. Impressively, the company is now on track to achieve at least $4 billion in cost savings by the end of its FY24. The successful cost-cutting plan is quite significant here for obvious reasons, namely margin expansion.
As shown below, the company’s margins have cratered over the last several years, with PFE now hopeful the tide will change.
Image Source: Zacks Investment Research
Analysts have taken their earnings expectations higher across the board over recent months, undoubtedly a bullish sign.
Image Source: Zacks Investment Research
Philip Morris Reports Record Results
Philip Morris shares have been notably strong in 2024, up 45% and regularly seeing positive post-earnings reactions as of late. Impressively, the company delivered record net revenues and EPS, enjoying momentum across all regions and categories.
The favorable results have helped push the stock into a favorable Zacks Rank #2 (Buy), with the revisions trend for its current fiscal year shifting heavily bullish beginning in May.
Image Source: Zacks Investment Research
The company’s shipment volumes for its oral smoke-free products jumped nearly 25% year-over-year, primarily fueled by robust demand for ZYN nicotine pouches. Impressively, its nicotine pouch volumes jumped 41% in the US, whereas volumes outside of the US saw a 70% climb.
And to top it off, the company raised its quarterly dividend payout by a sold 3.8%, bringing the annualized tally to $5.40 per share. Philip Morris has long been a favorite among income-focused investors, regularly increasing its payouts over its history.
Image Source: Zacks Investment Research
THC Shares Remain Hot
Tenet Healthcare shares have been scorching-hot in 2024, up 115% and even outperforming many of the Mag 7 members. Favorable quarterly results have helped keep shares moving higher, popping following the latest print that delivered an adjusted EBITDA guidance upgrade.
The revisions trend for its current fiscal year has been remarkably bullish, with the current $10.72 Zacks Consensus EPS estimate up nearly 75% over the last year and suggesting 50% growth year-over-year. The stock sports a favorable Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
The company’s cash-generating abilities also saw a big boost, with free cash flow of $1.8 billion nearly 80% higher than the year-ago figure. Undoubtedly a positive, the company continued to aggressively buy back its shares throughout the period, scooping up $124 million worth.
As shown below, THC has regularly bought its shares back over recent years, helping establish a small floor.
Image Source: Zacks Investment Research
Bottom Line
The 2024 Q3 earnings season continues to roll along, with a nice variety of companies already delivering quarterly results.
And throughout the period, we’ve seen many companies deliver robust results, a list that includes Pfizer (PFE - Free Report) , Philip Morris (PM - Free Report) , and Tenet Healthcare (THC - Free Report) . All three companies raised their outlooks following their results, providing a bullish outlook.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3 Stocks to Buy Following Robust Quarterly Results
The 2024 Q3 earnings season continues to chug along, with a decent chunk of S&P 500 companies already delivering their results.
And throughout the period, several companies, including Pfizer (PFE - Free Report) , Philip Morris (PM - Free Report) , and Tenet Healthcare (THC - Free Report) , have stolen the spotlight, with each raising guidance.
Let’s take a closer look at the reports.
Pfizer Sees Bullish Outlook
Pfizer shares have largely been disappointing in 2024, up 3% and widely underperforming relative to the S&P 500. Still, the recent set of favorable results could perk shares up in the near term, with the company raising its current-year sales guidance by a solid $1.5 billion while also raising its adjusted EPS outlook.
Image Source: Zacks Investment Research
Strong demand for Paxlovid following a recent wave of COVID-19 helped drive the better-than-expected results, with successful cost-cutting measures also providing tailwinds. Impressively, the company is now on track to achieve at least $4 billion in cost savings by the end of its FY24. The successful cost-cutting plan is quite significant here for obvious reasons, namely margin expansion.
As shown below, the company’s margins have cratered over the last several years, with PFE now hopeful the tide will change.
Image Source: Zacks Investment Research
Analysts have taken their earnings expectations higher across the board over recent months, undoubtedly a bullish sign.
Image Source: Zacks Investment Research
Philip Morris Reports Record Results
Philip Morris shares have been notably strong in 2024, up 45% and regularly seeing positive post-earnings reactions as of late. Impressively, the company delivered record net revenues and EPS, enjoying momentum across all regions and categories.
The favorable results have helped push the stock into a favorable Zacks Rank #2 (Buy), with the revisions trend for its current fiscal year shifting heavily bullish beginning in May.
Image Source: Zacks Investment Research
The company’s shipment volumes for its oral smoke-free products jumped nearly 25% year-over-year, primarily fueled by robust demand for ZYN nicotine pouches. Impressively, its nicotine pouch volumes jumped 41% in the US, whereas volumes outside of the US saw a 70% climb.
And to top it off, the company raised its quarterly dividend payout by a sold 3.8%, bringing the annualized tally to $5.40 per share. Philip Morris has long been a favorite among income-focused investors, regularly increasing its payouts over its history.
Image Source: Zacks Investment Research
THC Shares Remain Hot
Tenet Healthcare shares have been scorching-hot in 2024, up 115% and even outperforming many of the Mag 7 members. Favorable quarterly results have helped keep shares moving higher, popping following the latest print that delivered an adjusted EBITDA guidance upgrade.
The revisions trend for its current fiscal year has been remarkably bullish, with the current $10.72 Zacks Consensus EPS estimate up nearly 75% over the last year and suggesting 50% growth year-over-year. The stock sports a favorable Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
The company’s cash-generating abilities also saw a big boost, with free cash flow of $1.8 billion nearly 80% higher than the year-ago figure. Undoubtedly a positive, the company continued to aggressively buy back its shares throughout the period, scooping up $124 million worth.
As shown below, THC has regularly bought its shares back over recent years, helping establish a small floor.
Image Source: Zacks Investment Research
Bottom Line
The 2024 Q3 earnings season continues to roll along, with a nice variety of companies already delivering quarterly results.
And throughout the period, we’ve seen many companies deliver robust results, a list that includes Pfizer (PFE - Free Report) , Philip Morris (PM - Free Report) , and Tenet Healthcare (THC - Free Report) . All three companies raised their outlooks following their results, providing a bullish outlook.